News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
37–45
Matches
45
Sources here
6
Companies here
1
Search results Stored financial headlines

Active search

45 matching headlines

Ticker or company: RCKTMain company stories
Clear

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

Stock Titan Earnings Main company 🇺🇸 United States

If You Invested $1,000 in Rocket Pharmaceu (RCKT)

This article analyzes the historical performance of investing $1,000 in Rocket Pharmaceuticals (RCKT) over different periods, comparing it to the S&P 500. It details RCKT's stock value depreciation over 5 and 10 years, despite a slight gain in the last year, and provides an …

RCKT main company
Sharemaestro market context Price below Trend Line 52 weeks -4.7% RCKT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Rocket Pharmaceuticals Inc (RCKT) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Rocket Pharmaceuticals Inc (RCKT), noting its current valuation score of 6.70, which ranks 301 out of 386 in the Biotechnology & Medical Research industry. The company's P/E ratio stands at -1.70, and it is mentioned that relevant …

RCKT main company
Sharemaestro market context Price below Trend Line 52 weeks -4.7% RCKT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
DirectorsTalk Interviews Earnings Main company 🇺🇸 United States

Rocket Pharmaceuticals (RCKT) Stock Analysis: Exploring a Potential 186% Upside in Genetic Therapy Innovation

Rocket Pharmaceuticals (RCKT) is a late-stage biotechnology company focused on genetic therapies for rare and life-threatening diseases, with a potential upside of 186.17% based on analyst price targets. Despite being in an investment phase with a negative P/E ratio, its innovative pipeline targeting severe …

RCKT main company
Sharemaestro market context Price below Trend Line 52 weeks -4.7% RCKT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
MLQ.ai Earnings Main company 🇺🇸 United States

Frontier tech research, news & data

The article provides a detailed look at ROCKET PHARMACEUTICALS, INC.'s cash on hand (RCKT) from FY2013 through Q1 FY26, sourced from SEC EDGAR. It highlights a decrease in cash and equivalents from $163.6M in FY2024 to $77.6M in FY2025, further dropping to $49.6M in …

RCKT main company
Sharemaestro market context Price below Trend Line 52 weeks -4.7% RCKT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Ad-hoc-news.de Earnings Main company 🇺🇸 United States

Rocket Pharmaceuticals stock steadies as gene therapy pipeline advances and cash runway extends

Rocket Pharmaceuticals (RCKT) stock is gaining investor interest due to its advancing gene therapy pipeline and an extended cash runway, which supports trials into 2027. Despite reporting operating losses, the company modestly beat analyst expectations, and its Danon disease gene therapy program is showing …

RCKT main company
Sharemaestro market context Price below Trend Line 52 weeks -4.7% RCKT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Market update Main company 🇺🇸 United States

ETFs Investing in Rocket Pharmaceuticals, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of Rocket Pharmaceuticals, Inc. (9IP1). It provides a detailed table including each ETF's market value, weight of Rocket Pharmaceuticals in the fund, issuer, management style, expense ratio, assets under management (AUM), price, change …

RCKT main company
Sharemaestro market context Price below Trend Line 52 weeks -4.7% RCKT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Enterprise value to EBITDA forward of Rocket Pharmaceuticals, Inc. – DUS:9IP1

This article provides financial information for Rocket Pharmaceuticals, Inc. (DUS:9IP1) on the Dusseldorf Stock Exchange, specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed with no trades at the time of publication. The page is part of …

RCKT main company
Sharemaestro market context Price below Trend Line 52 weeks -4.7% RCKT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Enterprise value to revenue forward of Rocket Pharmaceuticals, Inc. – NASDAQ:RCKTW

This article displays the "Enterprise value to revenue forward" metric for Rocket Pharmaceuticals, Inc., publicly traded under the NASDAQ:RCKTW symbol. The content provides a basic financial overview for investors and traders on TradingView. The presented value focuses on the forward-looking enterprise value to revenue …

RCKT main company
Sharemaestro market context Price below Trend Line 52 weeks -4.7% RCKT stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

RCKTW SEC Filings - ROCKET PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms

This page provides access to ROCKET PHARMACEUTICALS INC SEC filings (Ticker: RCKTW), including 10-K, 10-Q, 8-K, and insider trading forms. It features AI-generated summaries, sentiment and impact scores, and corresponding end-of-day stock performance. Recent filings include Form 144 notices for insider sales and a …

RCKT main company
Sharemaestro market context Price below Trend Line 52 weeks -4.7% RCKT stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context